Testing Demand Will Increase as Pandemic Worsens

While there are hopes for widespread vaccinations in the U.S., the pandemic has shown no signs of slowing. Globally, there are now 102.66 million cases. In the U.S., the count is up to 26 million. In India, it’s up to 10.7 million. In Brazil, 9.1 million. In Russia, 3.8 million. In the UK, 3.8 million. Hospitals have been strained. In fact, according to the Associated Press, “An Associated Press analysis of federal hospital data shows that since November, the share of U.S. hospitals nearing the breaking point has doubled. More than 40% of Americans now live in areas running out of ICU space, with only 15% of beds still available.” Along the way, it’s increasing the need for testing, which is also seeing incredible demand. That’s where companies like Datametrex AI Limited (TSXV:DM)(OTC:DTMXF), Laboratory Corp. of America Holdings (NYSE:LH), Abbott Laboratories (NYSE:ABT), Quest Diagnostics Inc. (NYSE:DGX), and Chembio Diagnostics Inc. (NASDAQ:CEMI) are able to help.

Datametrex AI Limited (TSXV:DM)(OTC:DTMXF) BREAKING NEWS: Datametrex AI Limited  is pleased to announce that it has received a Purchase Order from a Canadian mining company for COVID-19 test kits manufactured by 1drop Inc.,and ancillary products. The total gross sales amount of the sales is approximately $250,000 CAD, excluding shipping and courier fees.

Under the terms of the sale to the Purchaser, Datametrex will provide 1drop COVID-19 qPCR Detection Kits, a PCR machine, an RNA extraction machine, and RNA extraction kits. Datametrex anticipates that it has a little or no upfront costs associated with the sale of the test kits. All of the items are shipped directly from manufacturers to the purchaser’s mine operating sites. “This further confirms Datametrex’s approach with its diverse COVID-19 product portfolio of health security products and services," stated Marshall Gunter, CEO of Datametrex.

Other related developments from around the markets include:

Laboratory Corp. of America Holdings (NYSE:LH), a leading global life sciences company, announced that Dr. Deborah Ann Sesok-Pizzini has been appointed Chief Medical Officer of Labcorp Diagnostics, following the retirement of Dr. Dot Adcock in April 2021. Dr. Sesok-Pizzini assumed the role starting on January 11, 2021. Dr. Sesok-Pizzini joins Labcorp with over two decades of experience in healthcare. Prior to joining Labcorp, she held multiple appointments with The Children’s Hospital of Philadelphia, including Patient Safety Officer, Chief of the Division of Transfusion Medicine and Vice-Chief of Pathology and Laboratory Medicine. She was also a professor of clinical pathology and laboratory medicine at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA.

Abbott Laboratories (NYSE:ABT) announced financial results for the fourth quarter and full year ended Dec. 31, 2020, and issued its financial outlook for 2021. "Despite challenging conditions, we achieved double-digit EPS growth, delivered ground-breaking innovation and advanced our new product pipeline in 2020," said Robert B. Ford, president and chief executive officer, Abbott. "We exited the year with a lot of momentum and are forecasting EPS growth of more than 35 percent in 2021."

Quest Diagnostics Inc. (NYSE:DGX), the world's leading provider of diagnostic information services, announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to provide genomic sequencing to identify new mutations in, and patterns of transmission of SARS-CoV-2, the virus that causes COVID-19. Financial terms of the agreement are not disclosed. The goal of the collaboration is to aid the CDC in conducting a large-scale longitudinal genomic survey of the SARS-CoV-2 virus using a random set of samples collected from Quest's labs across the United States. The company will perform the sequencing from its advanced diagnostics laboratory in San Juan Capistrano, Calif. Viruses can mutate over time. In recent weeks, highly transmissible variants of the SARS-CoV-2 virus first discovered in the United Kingdom and South Africa have been identified in the United States.  

Chembio Diagnostics Inc. (NASDAQ:CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced the CE mark for the DPP SARS-CoV-2 Antigen and IgM/IgG test systems, providing regulatory approval to register and market both test systems in the European Union and other geographies that accept the CE mark. The Company also announced that it has entered into a distribution agreement with Luas Diagnostics, which will commence system sales immediately while serving as the exclusive commercial partner for all of Chembio’s products in the United Kingdom and Ireland. “Having the CE mark for both COVID-19 test systems is indicative of the strong performance and reliability of the DPP system. These tests can assist clinicians across Europe with the diagnosis and management of patients and understanding virus exposure levels in their communities through testing in a variety of point-of-care settings,” stated Richard Eberly, Chembio’s President and Chief Executive Officer. “Partnering with Luas Diagnostics expands our global commercial footprint in the important markets of the United Kingdom and Ireland. We are very excited to offer our entire portfolio of products through this highly respected and connected organization.”

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Datametrex AI Limited by a third party. We own ZERO shares of Datametrex AI Limited. Please click here for full disclaimer.

Contact Information:
2818047972
[email protected]